HONG KONG – Singapore-based Tessa Therapeutics Ltd. and China-Singapore Guangzhou Knowledge City (CSGKC) are committing a combined $120 million to establish a joint venture to advance cell therapies targeting prevalent cancers in China.
Kleo Pharmaceuticals Inc., of New Haven, Conn., said that CD38-ARM, a CD38-targeting antibody recruiting molecule, or ARM, designed to treat multiple myeloma, will be its first candidate to move into the clinic. Human studies are expected to begin next year. The molecule, the first to emerge from Kleo's 2017 alliance with Peptidream Inc., of Tokyo, was selected on the basis of preclinical safety and efficacy signals.
Harbour Biomed Therapeutics Ltd., of Shanghai, and Erasmus Medical Center in Rotterdam, the Netherlands, signed a 10-year memorandum of understanding to enable a broad range of joint basic, translational and clinical research activities aimed at developing next-generation biotherapeutics for the treatment of cancer and immunological diseases.
Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan, appointed Katsuyuki Kaitonaka to the corporate department of Sumitomo Pharmaceuticals (Suzhou) Co. Ltd., effective July 1, and named Akihisa Fukushima senior fellow, vaccine project, drug research division, effective July 1.
HONG KONG – China-based Hansoh Pharmaceutical Group Co. Ltd. had a strong debut on Hong Kong's stock market and raised $1 billion on June 14 – despite widespread protests and a political crisis here – becoming the biggest health care IPO in Hong Kong this year.
HONG KONG – Swedish biopharma Calliditas Therapeutics AB and Singapore-headquartered pharmaceutical company Everest Medicines II Ltd. agreed to develop and commercialize Nefecon for the treatment of IgA nephropathy in greater China and Singapore in a deal valued at more than $121 million.
RSS